These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 23649520)

  • 1. Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes.
    Jørgensen NB; Dirksen C; Bojsen-Møller KN; Jacobsen SH; Worm D; Hansen DL; Kristiansen VB; Naver L; Madsbad S; Holst JJ
    Diabetes; 2013 Sep; 62(9):3044-52. PubMed ID: 23649520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery.
    Svane MS; Bojsen-Møller KN; Nielsen S; Jørgensen NB; Dirksen C; Bendtsen F; Kristiansen VB; Hartmann B; Holst JJ; Madsbad S
    Am J Physiol Endocrinol Metab; 2016 Apr; 310(7):E505-14. PubMed ID: 26786780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roux-en-Y gastric bypass-induced improvement of glucose tolerance and insulin resistance in type 2 diabetic rats are mediated by glucagon-like peptide-1.
    Liu Y; Zhou Y; Wang Y; Geng D; Liu J
    Obes Surg; 2011 Sep; 21(9):1424-31. PubMed ID: 21479766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass.
    Bojsen-Møller KN
    Dan Med J; 2015 Apr; 62(4):B5057. PubMed ID: 25872541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exaggerated release and preserved insulinotropic action of glucagon-like peptide-1 underlie insulin hypersecretion in glucose-tolerant individuals after Roux-en-Y gastric bypass.
    Dirksen C; Bojsen-Møller KN; Jørgensen NB; Jacobsen SH; Kristiansen VB; Naver LS; Hansen DL; Worm D; Holst JJ; Madsbad S
    Diabetologia; 2013 Dec; 56(12):2679-87. PubMed ID: 24048673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral, but not central, GLP-1 receptor signaling is required for improvement in glucose tolerance after Roux-en-Y gastric bypass in mice.
    Carmody JS; Muñoz R; Yin H; Kaplan LM
    Am J Physiol Endocrinol Metab; 2016 May; 310(10):E855-61. PubMed ID: 27026085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roux-en-Y gastric bypass compared with equivalent diet restriction: Mechanistic insights into diabetes remission.
    Pop LM; Mari A; Zhao TJ; Mitchell L; Burgess S; Li X; Adams-Huet B; Lingvay I
    Diabetes Obes Metab; 2018 Jul; 20(7):1710-1721. PubMed ID: 29532631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones.
    Nannipieri M; Baldi S; Mari A; Colligiani D; Guarino D; Camastra S; Barsotti E; Berta R; Moriconi D; Bellini R; Anselmino M; Ferrannini E
    J Clin Endocrinol Metab; 2013 Nov; 98(11):4391-9. PubMed ID: 24057293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preserved Insulin Secretory Capacity and Weight Loss Are the Predominant Predictors of Glycemic Control in Patients With Type 2 Diabetes Randomized to Roux-en-Y Gastric Bypass.
    Nguyen KT; Billington CJ; Vella A; Wang Q; Ahmed L; Bantle JP; Bessler M; Connett JE; Inabnet WB; Thomas A; Ikramuddin S; Korner J
    Diabetes; 2015 Sep; 64(9):3104-10. PubMed ID: 25901097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of endogenous glucagon-like peptide-1 to changes in glucose metabolism and islet function in people with type 2 diabetes four weeks after Roux-en-Y gastric bypass (RYGB).
    Shah M; Laurenti MC; Dalla Man C; Ma J; Cobelli C; Rizza RA; Vella A
    Metabolism; 2019 Apr; 93():10-17. PubMed ID: 30586575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass.
    Salehi M; Gastaldelli A; D'Alessio DA
    Gastroenterology; 2014 Mar; 146(3):669-680.e2. PubMed ID: 24315990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute effects of gastric bypass versus gastric restrictive surgery on beta-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes.
    Kashyap SR; Daud S; Kelly KR; Gastaldelli A; Win H; Brethauer S; Kirwan JP; Schauer PR
    Int J Obes (Lond); 2010 Mar; 34(3):462-71. PubMed ID: 20029383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance.
    Jørgensen NB; Jacobsen SH; Dirksen C; Bojsen-Møller KN; Naver L; Hvolris L; Clausen TR; Wulff BS; Worm D; Lindqvist Hansen D; Madsbad S; Holst JJ
    Am J Physiol Endocrinol Metab; 2012 Jul; 303(1):E122-31. PubMed ID: 22535748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastrointestinal Hormones and β-Cell Function After Gastric Bypass and Sleeve Gastrectomy: A Randomized Controlled Trial (Oseberg).
    Fatima F; Hjelmesæth J; Birkeland KI; Gulseth HL; Hertel JK; Svanevik M; Sandbu R; Småstuen MC; Hartmann B; Holst JJ; Hofsø D
    J Clin Endocrinol Metab; 2022 Jan; 107(2):e756-e766. PubMed ID: 34463768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic responses to xenin-25 are altered in humans with Roux-en-Y gastric bypass surgery.
    Sterl K; Wang S; Oestricker L; Wallendorf MJ; Patterson BW; Reeds DN; Wice BM
    Peptides; 2016 Aug; 82():76-84. PubMed ID: 27288245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery.
    Svane MS; Jørgensen NB; Bojsen-Møller KN; Dirksen C; Nielsen S; Kristiansen VB; Toräng S; Wewer Albrechtsen NJ; Rehfeld JF; Hartmann B; Madsbad S; Holst JJ
    Int J Obes (Lond); 2016 Nov; 40(11):1699-1706. PubMed ID: 27434221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide-1 effect on β-cell function varies according to diabetes remission status after Roux-en-Y gastric bypass.
    Shah A; Prasad M; Mark V; Holst JJ; Laferrère B
    Diabetes Obes Metab; 2022 Nov; 24(11):2081-2089. PubMed ID: 35676799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of acute dual SGLT1/SGLT2 inhibition on incretin release and glucose metabolism after gastric bypass surgery.
    Martinussen C; Veedfald S; Dirksen C; Bojsen-Møller KN; Svane MS; Wewer Albrechtsen NJ; van Hall G; Kristiansen VB; Fenger M; Holst JJ; Madsbad S
    Am J Physiol Endocrinol Metab; 2020 Jun; 318(6):E956-E964. PubMed ID: 32182123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GLP-1 plays a limited role in improved glycemia shortly after Roux-en-Y gastric bypass: a comparison with intensive lifestyle modification.
    Vetter ML; Wadden TA; Teff KL; Khan ZF; Carvajal R; Ritter S; Moore RH; Chittams JL; Iagnocco A; Murayama K; Korus G; Williams NN; Rickels MR
    Diabetes; 2015 Feb; 64(2):434-46. PubMed ID: 25204975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects.
    Jacobsen SH; Olesen SC; Dirksen C; Jørgensen NB; Bojsen-Møller KN; Kielgast U; Worm D; Almdal T; Naver LS; Hvolris LE; Rehfeld JF; Wulff BS; Clausen TR; Hansen DL; Holst JJ; Madsbad S
    Obes Surg; 2012 Jul; 22(7):1084-96. PubMed ID: 22359255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.